NOTV (Inotiv) Cash-to-Debt : 0.09 (As of Dec. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Inotiv Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Inotiv's cash to debt ratio for the quarter that ended in Dec. 2024 was 0.09.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Inotiv couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for Inotiv's Cash-to-Debt or its related term are showing as below:

NOTV' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 0.08 Max: 0.8
Current: 0.09

During the past 13 years, Inotiv's highest Cash to Debt Ratio was 0.80. The lowest was 0.01. And the median was 0.08.

NOTV's Cash-to-Debt is ranked worse than
89.59% of 221 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.22 vs NOTV: 0.09

Inotiv Cash-to-Debt Historical Data

The historical data trend for Inotiv's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Inotiv Cash-to-Debt Chart

Inotiv Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Cash-to-Debt

Get a 7-Day Free Trial

0.04

0.80

0.05

0.09

0.05

Inotiv Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial															0.05	0.08	0.03	0.05	0.09

Competitive Comparison of Inotiv's Cash-to-Debt

For the Diagnostics & Research subindustry, Inotiv's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inotiv's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Inotiv's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Inotiv Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Inotiv's Cash to Debt Ratio for the fiscal year that ended in Sep. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	21.432	/	(15.312	+	429.811)
	=	0.05

Inotiv's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	38.043	/	(12.542	+	434.566)
	=	0.09

Inotiv (NAS:NOTV) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Inotiv Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Inotiv's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Inotiv Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inotiv Inc (NAS:NOTV) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

2701 Kent Avenue, West Lafayette, IN, USA, 47906

Website

https://www.inotivco.com

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

Executives

John E Sagartz	director, officer: Chief Strategy Officer	19 WORTHINGTON ACCESS DRIVE, MARYLAND HEIGHTS MO 63043
Robert Jr. Leasure	director, officer: President and CEO	C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Beth Taylor	officer: Chief Financial Officer	3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Jeffrey Brennan Freeman	officer: VP-Finance & Corp. Controller	2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
David Landman	director	2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
John Gregory Beattie	officer: Chief Operating Officer	C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Nigel Brown	director	250 PEHLE AVENUE, SUITE 600, SADDLE BROOK NJ 07663
Michael Garrett	officer: Chief Commercial Officer	250 PEHLE DRIVE, SUITE 601, SADDLE BROOK NJ 07663
Andrea Castetter	officer: SVP, Gen. Counsel & Secretary	2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Mary Theresa Coelho	director	52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Jeffrey Arthur Krupp	officer: Chief Human Resources Officer	2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
William D Pitchford	officer: Chief Human Resources Officer	1000 SAGAMORE PARKWAY SOUTH, LAFAYETTE IN 47905
R Matthew Neff	director	535 N. COLLEGE DRIVE, CARMEL IN 46032
Richard Allen Johnson	director	2701 KENT AVE, WEST LAFAYETTE MI 47906
Davis Gregory Cole	director	C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906